Brief Title
Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working
Protocol ID
NCT05633381
Brief Summary
Conditions: Locally Advanced Leiomyosarcoma; Metastatic Leiomyosarcoma; Stage III Uterine Corpus Leiomyosarcoma AJCC v8; Stage IV Uterine Corpus Leiomyosarcoma AJCC v8; Unresectable Leiomyosarcoma; Uterine Corpus Leiomyosarcoma
Interventions: Drug: Olaparib; Drug: Temozolomide; Drug: Trabectedin; Drug: Pazopanib
Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI)
Recruiting
Interventions: Drug: Olaparib; Drug: Temozolomide; Drug: Trabectedin; Drug: Pazopanib
Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI)
Recruiting
Pub Date:
Thursday, December 1, 2022 - 10:00am